1
|
Yousefpour P, Varanko A, Subrahmanyan R, Chilkoti A. Recombinant Fusion of Glucagon‐Like Peptide‐1 and an Albumin Binding Domain Provides Glycemic Control for a Week in Diabetic Mice. ADVANCED THERAPEUTICS 2020. [DOI: 10.1002/adtp.202000073] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Parisa Yousefpour
- Department of Biomedical Engineering Duke University Durham NC 27708 USA
| | - Anastasia Varanko
- Department of Biomedical Engineering Duke University Durham NC 27708 USA
| | | | - Ashutosh Chilkoti
- Department of Biomedical Engineering Duke University Durham NC 27708 USA
| |
Collapse
|
2
|
Yousefpour P, Ahn L, Tewksbury J, Saha S, Costa SA, Bellucci JJ, Li X, Chilkoti A. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2019; 15:e1804452. [PMID: 30756483 PMCID: PMC8114561 DOI: 10.1002/smll.201804452] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 01/11/2019] [Indexed: 05/21/2023]
Abstract
Short circulation time and off-target toxicity are the main challenges faced by small-molecule chemotherapeutics. To overcome these shortcomings, an albumin-binding peptide conjugate of chemotherapeutics is developed that binds specifically to endogenous albumin and harnesses its favorable pharmacokinetics and pharmacodynamics for drug delivery to tumors. A protein-G-derived albumin-binding domain (ABD) is conjugated with doxorubicin (Dox) via a pH-sensitive linker. One to two Dox molecules are conjugated to ABD without loss of aqueous solubility. The albumin-binding ABD-Dox conjugate exhibits nanomolar affinity for human and mouse albumin, and upon administration in mice, shows a plasma half-life of 29.4 h, which is close to that of mouse albumin. Additionally, 2 h after administration, ABD-Dox exhibits an approximately 4-fold higher concentration in the tumor than free Dox. Free Dox clears quickly from the tumor, while ABD-Dox maintains a steady concentration in the tumor for at least 72 h, so that its relative accumulation at 72 h is ≈120-fold greater than that of free Dox. The improved pharmacokinetics and biodistribution of ABD-Dox result in enhanced therapeutic efficacy in syngeneic C26 colon carcinoma and MIA PaCa-2 pancreatic tumor xenografts, compared with free Dox and aldoxorubicin, an albumin-reactive Dox prodrug currently in clinical development.
Collapse
Affiliation(s)
- Parisa Yousefpour
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Lucie Ahn
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Joel Tewksbury
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Soumen Saha
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Simone A Costa
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Joseph J Bellucci
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Xinghai Li
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Ashutosh Chilkoti
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| |
Collapse
|
3
|
ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis. Int J Mol Sci 2018; 19:ijms19103089. [PMID: 30304852 PMCID: PMC6213189 DOI: 10.3390/ijms19103089] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 10/04/2018] [Accepted: 10/06/2018] [Indexed: 12/14/2022] Open
Abstract
Interleukin 17 (IL-17) and its cognate receptor A (IL-17RA) play a crucial role in Th17 cells-mediated pro-inflammatory pathway and pathogenesis of several autoimmune disorders including psoriasis. IL-17 is mainly produced by activated Th-17 helper cells upon stimulation by IL-23 and, via binding to its receptors, mediates IL-17-driven cell signaling in keratinocytes. Hyper-proliferation of keratinocytes belongs to major clinical manifestations in psoriasis. To modulate IL-17-mediated inflammatory cascade, we generated a unique collection of IL-17RA-targeting protein binders that prevent from binding of human IL-17A cytokine to its cell-surface receptor. To this goal, we used a highly complex combinatorial library derived from scaffold of albumin-binding domain (ABD) of streptococcal protein G, and ribosome display selection, to yield a collection of ABD-derived high-affinity ligands of human IL-17RA, called ARS binders. From 67 analyzed ABD variants, 7 different sequence families were identified. Representatives of these groups competed with human IL-17A for binding to recombinant IL-17RA receptor as well as to IL-17RA-Immunoglobulin G chimera, as tested in enzyme-linked immunosorbent assay (ELISA). Five ARS variants bound to IL-17RA-expressing THP-1 cells and blocked binding of human IL-17 cytokine to the cell surface, as tested by flow cytometry. Three variants exhibited high-affinity binding with a nanomolar Kd value to human keratinocyte HaCaT cells, as measured using Ligand Tracer Green Line. Upon IL-17-stimulated activation, ARS variants inhibited secretion of Gro-α (CXCL1) by normal human skin fibroblasts in vitro. Thus, we identified a novel class of inhibitory ligands that might serve as immunosuppressive IL-17RA-targeted non-IgG protein antagonists.
Collapse
|
4
|
Yu W, Wang L, Wang M, Liu S, Li W, Wang X, Li X, Yu S, Yao D, Ma J, Yu L, Chen J, Feng Z, Cui Y. Identification and characterization of CD4 + T cell epitopes on manganese transport protein C of Staphylococcus aureus. Microb Pathog 2017; 112:30-37. [PMID: 28942173 DOI: 10.1016/j.micpath.2017.09.045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 08/26/2017] [Accepted: 09/19/2017] [Indexed: 11/29/2022]
Abstract
Manganese transport protein C (MntC) of Staphylococcus aureus represents an excellent vaccine-candidate antigen. The important role of CD4+ T cells in effective immunity against S. aureus infection was shown; however, CD4+ T cell-specific epitopes on S. aureus MntC have not been well identified. Here, we used bioinformatics prediction algorithms to evaluate and identify nine candidate epitopes within MntC. Our results showed that peptide M8 emulsified in Freund's adjuvant induced a much higher cell-proliferation rate as compared with controls. Additionally, CD4+ T cells stimulated with peptide M8 secreted significantly higher levels of interferon-γ and interleukin-17A. These results suggested that peptide M8 represented an H-2d (I-E)-restricted Th17-specific epitope.
Collapse
Affiliation(s)
- Wei Yu
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Lizi Wang
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Mengyao Wang
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Shuo Liu
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Wanyu Li
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Xintong Wang
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Xiaoting Li
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Simiao Yu
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Di Yao
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Jinzhu Ma
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Liquan Yu
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Jing Chen
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Zhenyue Feng
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China
| | - Yudong Cui
- College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China.
| |
Collapse
|
5
|
Křížová L, Kuchař M, Petroková H, Osička R, Hlavničková M, Pelák O, Černý J, Kalina T, Malý P. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells. Autoimmunity 2017; 50:102-113. [DOI: 10.1080/08916934.2016.1272598] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Lucie Křížová
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center, Vestec, Czech Republic,
| | - Milan Kuchař
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center, Vestec, Czech Republic,
| | - Hana Petroková
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center, Vestec, Czech Republic,
| | - Radim Osička
- Laboratory of Molecular Biology of the Bacterial Pathogens, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic,
| | - Marie Hlavničková
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center, Vestec, Czech Republic,
| | - Ondřej Pelák
- CLIP, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic, and
| | - Jiří Černý
- Laboratory of Biomolecular Recognition, Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center, Vestec, Czech Republic
| | - Tomáš Kalina
- CLIP, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic, and
| | - Petr Malý
- Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center, Vestec, Czech Republic,
| |
Collapse
|
6
|
Identification and characterization of CD4+ T-cell epitopes on GapC protein of Streptococcus dysgalactiae. Microb Pathog 2016; 91:46-53. [DOI: 10.1016/j.micpath.2015.11.025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2015] [Accepted: 11/25/2015] [Indexed: 12/19/2022]
|
7
|
Early implementation of QbD in biopharmaceutical development: a practical example. BIOMED RESEARCH INTERNATIONAL 2015; 2015:605427. [PMID: 26075248 PMCID: PMC4449898 DOI: 10.1155/2015/605427] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Revised: 02/13/2015] [Accepted: 02/15/2015] [Indexed: 02/08/2023]
Abstract
In drug development, the “onus” of the low R&D efficiency has been put traditionally onto the drug discovery process (i.e., finding the right target or “binding” functionality). Here, we show that manufacturing is not only a central component of product success, but also that, by integrating manufacturing and discovery activities in a “holistic” interpretation of QbD methodologies, we could expect to increase the efficiency of the drug discovery process as a whole. In this new context, early risk assessment, using developability methodologies and computational methods in particular, can assist in reducing risks during development in a cost-effective way. We define specific areas of risk and how they can impact product quality in a broad sense, including essential aspects such as product efficacy and patient safety. Emerging industry practices around developability are introduced, including some specific examples of applications to biotherapeutics. Furthermore, we suggest some potential workflows to illustrate how developability strategies can be introduced in practical terms during early drug development in order to mitigate risks, reduce drug attrition and ultimately increase the robustness of the biopharmaceutical supply chain. Finally, we also discuss how the implementation of such methodologies could accelerate the access of new therapeutic treatments to patients in the clinic.
Collapse
|
8
|
Abstract
Affibody molecules are small and robust non-immunoglobulin affinity ligands capable of binding to a wide range of protein targets. They are selected from combinatorial libraries based on a 58 amino acid, three-alpha-helical Z-domain scaffold. They share no sequence or structural homologies to antibodies and in contrast to antibodies they can be functionally produced both by peptide synthesis and by recombinant expression in Escherichia coli. Protein engineering is used to adapt Affibody molecules binding to a target of interest to the specific demands imposed by the intended application. Obviously, the optimal molecule for molecular imaging will be different from the optimal molecule for therapy. Here, we describe general strategies to optimize Affibody molecules for diagnostic imaging and therapy applications.
Collapse
|
9
|
Beck A, Klinguer-Hamour C, Bussat MC, Champion T, Haeuw JF, Goetsch L, Wurch T, Sugawara M, Milon A, Van Dorsselaer A, Nguyen T, Corvaïa N. Peptides as tools and drugs for immunotherapies. J Pept Sci 2007; 13:588-602. [PMID: 17602441 DOI: 10.1002/psc.852] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Peptides are essential tools for discovery and pre-clinical and pharmaceutical development of viral and cancer vaccines ('active immunotherapies') as well as for therapeutic antibodies ('passive immunotherapies'). They help to trigger and analyze immune responses at a molecular level (B-cell, T-helper and CTL epitopes). They contribute largely to the design of new vaccine candidates and to the generation of monoclonal antibodies. They are also valuable analytical reference compounds for the structural characterisation by liquid chromatography and mass spectrometry of recombinant proteins used as biopharmaceuticals. As for other therapeutic applications, formulation, solubilisation, batch consistency and stability, issues have to be addressed to allow the pre-clinical and clinical development of this class of compounds as immunotherapeutic drugs. In the present review, three case studies dealing with (i) the design and the characterisation of Respiratory Syntycial Virus subunit vaccines, (ii) peptide-based melanoma vaccines, and (iii) therapeutic monoclonal antibodies, all investigated in clinical trials, are reported and discussed.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/therapeutic use
- Antigens, Viral/chemistry
- Antigens, Viral/genetics
- Cancer Vaccines/genetics
- Cancer Vaccines/immunology
- Epitopes, B-Lymphocyte/genetics
- Epitopes, T-Lymphocyte/genetics
- Humans
- Immunotherapy/methods
- Mice
- Models, Immunological
- Models, Molecular
- Molecular Sequence Data
- Peptide Mapping
- Peptides/immunology
- Peptides/therapeutic use
- Respiratory Syncytial Virus Vaccines/genetics
- Respiratory Syncytial Virus Vaccines/immunology
- Respiratory Syncytial Virus, Human/genetics
- Respiratory Syncytial Virus, Human/immunology
Collapse
Affiliation(s)
- Alain Beck
- Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon III, F74164 Saint-Julien-en-Genevois, Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|